PH12015501722A1 - Solid dispersion comprising amorphous cilostazol - Google Patents
Solid dispersion comprising amorphous cilostazolInfo
- Publication number
- PH12015501722A1 PH12015501722A1 PH12015501722A PH12015501722A PH12015501722A1 PH 12015501722 A1 PH12015501722 A1 PH 12015501722A1 PH 12015501722 A PH12015501722 A PH 12015501722A PH 12015501722 A PH12015501722 A PH 12015501722A PH 12015501722 A1 PH12015501722 A1 PH 12015501722A1
- Authority
- PH
- Philippines
- Prior art keywords
- solid dispersion
- cilostazol
- amorphous cilostazol
- methacrylic acid
- acid copolymer
- Prior art date
Links
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004588 cilostazol Drugs 0.000 title abstract 3
- 239000007962 solid dispersion Substances 0.000 title abstract 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 abstract 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 abstract 2
- LRDIEHDJWYRVPT-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 LRDIEHDJWYRVPT-UHFFFAOYSA-N 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013021475 | 2013-02-06 | ||
| PCT/JP2014/053232 WO2014123244A1 (en) | 2013-02-06 | 2014-02-05 | Solid dispersion comprising amorphous cilostazol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12015501722B1 PH12015501722B1 (en) | 2015-11-09 |
| PH12015501722A1 true PH12015501722A1 (en) | 2015-11-09 |
Family
ID=50184966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015501722A PH12015501722A1 (en) | 2013-02-06 | 2015-08-05 | Solid dispersion comprising amorphous cilostazol |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9555026B2 (enExample) |
| EP (1) | EP2953615B1 (enExample) |
| JP (2) | JP5980449B2 (enExample) |
| KR (1) | KR102205192B1 (enExample) |
| CN (1) | CN105050586B (enExample) |
| AR (1) | AR095143A1 (enExample) |
| AU (1) | AU2014215920B2 (enExample) |
| CA (1) | CA2899389C (enExample) |
| PH (1) | PH12015501722A1 (enExample) |
| TW (1) | TWI615157B (enExample) |
| WO (1) | WO2014123244A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110381945A (zh) * | 2017-02-10 | 2019-10-25 | 阿尔图姆制药股份有限公司 | 口服给予的镓（iii）配合物的组合物 |
| KR102114550B1 (ko) * | 2018-07-10 | 2020-05-22 | 삼육대학교산학협력단 | 생리학적 체내 동태 연구 모델링을 이용한 약제학적 조성물의 제조 방법 |
| WO2020227151A1 (en) * | 2019-05-03 | 2020-11-12 | Azora Therapeutics, Inc. | Compositions comprising indigo and/or an indigo derivative and methods of use thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH683673A5 (de) | 1991-10-01 | 1994-04-29 | Otsuka Pharma Co Ltd | Antithromboseharz, Antithromboseröhrchen, Antithrombosefilm und Antithromboseüberzug. |
| JP3799093B2 (ja) * | 1995-01-10 | 2006-07-19 | 大塚製薬株式会社 | 樹脂粒状物およびこれを含有する医療製剤 |
| AU4357096A (en) * | 1995-01-10 | 1996-07-31 | Otsuka Pharmaceutical Co., Ltd. | Resin particle, medical material and pharmaceutical preparation containing said resin particle |
| WO1997004782A1 (en) | 1995-07-26 | 1997-02-13 | Kyowa Hakko Kogyo Co., Ltd. | Solid dispersion or solid dispersion preparation of xanthine derivatives |
| JPH11246404A (ja) | 1998-03-04 | 1999-09-14 | Taiho Yakuhin Kogyo Kk | 吸収を改善した医薬組成物 |
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| JP4748839B2 (ja) | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
| EG23951A (en) | 1999-03-25 | 2008-01-29 | Otsuka Pharma Co Ltd | Cilostazol preparation |
| AU2003283769A1 (en) * | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| CN1241566C (zh) * | 2004-03-15 | 2006-02-15 | 深圳海王药业有限公司 | 西洛他唑固体分散体及其片剂制备方法 |
| JP2008521878A (ja) | 2004-12-02 | 2008-06-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 非晶質アトルバスタチンの医薬組成物及びその製造のための方法 |
| BRPI0620271A2 (pt) * | 2005-12-22 | 2011-11-08 | Otsuka Pharma Co Ltd | preparado com liberação sustentada contendo gránulos e método para produção do mesmo |
| US20100172989A1 (en) * | 2006-01-21 | 2010-07-08 | Abbott Laboratories | Abuse resistant melt extruded formulation having reduced alcohol interaction |
| JP2007308480A (ja) * | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | 腸溶性固体分散体を含んでなる固形製剤 |
| US20110165236A1 (en) * | 2006-09-22 | 2011-07-07 | Biokey, Inc. | Controlled release hydrogel formulation |
| KR20080076440A (ko) * | 2007-02-16 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
| JP2010526848A (ja) | 2007-05-11 | 2010-08-05 | エフ．ホフマン−ラ ロシュ アーゲー | 難溶性薬物用の医薬組成物 |
| JP4879351B2 (ja) * | 2007-10-19 | 2012-02-22 | 大塚製薬株式会社 | 医薬固形製剤 |
| AR071706A1 (es) * | 2008-05-15 | 2010-07-07 | Otsuka Pharma Co Ltd | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. |
| TW201010743A (en) | 2008-09-05 | 2010-03-16 | Otsuka Pharma Co Ltd | Pharmaceutical solid preparation |
| WO2011027656A1 (en) | 2009-09-04 | 2011-03-10 | Semiconductor Energy Laboratory Co., Ltd. | Transistor and display device |
| KR101282847B1 (ko) | 2011-07-27 | 2013-07-05 | 조선대학교산학협력단 | 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물 |
-
2014
- 2014-01-28 TW TW103103097A patent/TWI615157B/zh not_active IP Right Cessation
- 2014-02-04 AR ARP140100366A patent/AR095143A1/es unknown
- 2014-02-05 US US14/764,663 patent/US9555026B2/en not_active Expired - Fee Related
- 2014-02-05 CN CN201480018458.8A patent/CN105050586B/zh not_active Expired - Fee Related
- 2014-02-05 WO PCT/JP2014/053232 patent/WO2014123244A1/en not_active Ceased
- 2014-02-05 AU AU2014215920A patent/AU2014215920B2/en not_active Ceased
- 2014-02-05 KR KR1020157023661A patent/KR102205192B1/ko not_active Expired - Fee Related
- 2014-02-05 EP EP14706960.3A patent/EP2953615B1/en not_active Not-in-force
- 2014-02-05 CA CA2899389A patent/CA2899389C/en active Active
- 2014-02-05 JP JP2015555863A patent/JP5980449B2/ja not_active Expired - Fee Related
-
2015
- 2015-08-05 PH PH12015501722A patent/PH12015501722A1/en unknown
-
2016
- 2016-05-24 JP JP2016102975A patent/JP2016193915A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1218618A1 (en) | 2017-03-03 |
| KR102205192B1 (ko) | 2021-01-20 |
| AR095143A1 (es) | 2015-09-30 |
| CA2899389C (en) | 2021-02-16 |
| CN105050586A (zh) | 2015-11-11 |
| US9555026B2 (en) | 2017-01-31 |
| EP2953615B1 (en) | 2018-05-23 |
| CA2899389A1 (en) | 2014-08-14 |
| JP5980449B2 (ja) | 2016-08-31 |
| TW201440814A (zh) | 2014-11-01 |
| JP2016193915A (ja) | 2016-11-17 |
| WO2014123244A1 (en) | 2014-08-14 |
| KR20150115859A (ko) | 2015-10-14 |
| TWI615157B (zh) | 2018-02-21 |
| JP2016506948A (ja) | 2016-03-07 |
| CN105050586B (zh) | 2017-12-08 |
| AU2014215920A1 (en) | 2015-08-20 |
| EP2953615A1 (en) | 2015-12-16 |
| PH12015501722B1 (en) | 2015-11-09 |
| US20150366859A1 (en) | 2015-12-24 |
| AU2014215920B2 (en) | 2018-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283032A (en) | Preparations for oral administration of tofacitinib | |
| IL250752A0 (en) | Device with compounds for conduction to lungs, oral mucosa and brain | |
| EP3750590B8 (en) | Delivery capsule with threshold release | |
| IL244920B (en) | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | |
| IL263978B (en) | Amorphous latrovir and solid pharmaceutical preparations containing it and its uses | |
| IL244473A0 (en) | Low profile catheter for blockages | |
| EP3033136A4 (en) | Catheter insertion device | |
| EP3040022A4 (en) | Swallowing estimation device, information terminal device, and program | |
| EP3033009A4 (en) | Swallowing assessment and improvement systems and methods | |
| EP3040039A4 (en) | Medical insertion device | |
| IL243927A0 (en) | A digestive enzyme preparation suitable for administration to the intestine | |
| EP3179569A4 (en) | Connector, header used in said connector, and socket | |
| MX2016000158A (es) | Dispositivo de oclusion con canal con posibilidad de apertura. | |
| EP2898816A4 (en) | INTRODUCTION AID, INTRODUCTION BODY, AND INTRODUCTION DEVICE | |
| LT2983650T (lt) | Peroralinė farmacinė kompozicija, apimanti maskuoto skonio n-acetilcisteiną | |
| HRP20181554T4 (hr) | Tauroursodezoksikolna kiselina (tudca), namijenjena upotrebi u liječenju neurodegenerativnih poremećaja | |
| IL239958A (en) | A chewable oral preparation and process for preparing it | |
| PT2983647T (pt) | Administração de aine e composições, métodos e sistemas relacionados | |
| IL243432A0 (en) | Synthetic oligosaccharides for vaccination against p. aeruginosa and uses thereof | |
| AR095143A1 (es) | Dispersión sólida que comprende cilostazol amorfo y proceso de preparación | |
| IL241450A0 (en) | A preparation for oral administration used to bind aldehydes in the digestive tract | |
| EP2968127A4 (en) | LOW GLYCEROL PREPARATIONS FOR HIV TREATMENT AND PREVENTION | |
| Rezai | Oral reproduction of stories | |
| EP3050893A4 (en) | Glycoamino acid and use thereof | |
| IL245139A0 (en) | Methods and pharmaceutical compositions of estradiol for vaginal insertion |